| Item Type | Name |
|
Concept
|
Interleukin-6
|
|
Concept
|
Isotretinoin
|
|
Concept
|
Neurofibromin 2
|
|
Academic Article
|
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
|
|
Academic Article
|
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
|
|
Academic Article
|
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
|
|
Academic Article
|
No interest, no conflict.
|
|
Academic Article
|
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).
|
|
Academic Article
|
Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case.
|
|
Academic Article
|
Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer.
|
|
Academic Article
|
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
|
|
Academic Article
|
The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check.
|
|
Academic Article
|
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
|
|
Academic Article
|
Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
|
|
Academic Article
|
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).
|
|
Academic Article
|
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
|
|
Academic Article
|
Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.
|
|
Academic Article
|
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.
|
|
Academic Article
|
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial.
|
|
Academic Article
|
Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial.
|
|
Academic Article
|
Knowledge and distress in complex cancer care.
|
|
Academic Article
|
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.
|
|
Academic Article
|
NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases.
|
|
Academic Article
|
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.
|
|
Academic Article
|
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Emerging targets in kidney cancer: opportunities for drug development.
|
|
Academic Article
|
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.
|
|
Academic Article
|
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer.
|
|
Academic Article
|
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
|
|
Academic Article
|
Enrollment Barriers for Molecular Targeted Trials.
|
|
Academic Article
|
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
|
|
Academic Article
|
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics.
|
|
Academic Article
|
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
|
|
Academic Article
|
Optimizing the doses of cancer drugs after usual dose finding.
|
|
Academic Article
|
Bladder-Preserving Trimodality Therapy With Capecitabine.
|
|
Academic Article
|
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
|